Skip to main content
. 2022 Jul 2;10(7):1067. doi: 10.3390/vaccines10071067

Table 5.

Association between BNT162b2 and neurological adverse events from large-scale controlled surveillance studies.

Wan et al. [42] Li et al. [35] Shasha et al. [40] Barda et al. [25] Klein et al. [33] Patone et al. [38] Lai et al. [34]
Bell’s palsy Non-sig. Non-sig. Non-sig. Non-sig. Non-sig. Non-sig. Non-sig.
Paraesthesia - - RR: 1.21
EC: 39.5 per 10,000 person-years
Non-sig. - - -
Guillain-Barré syndrome - - Non-sig. - Non-sig Non-sig. -
Seizure or convulsion - - - Non-sig. Non-sig. - Non-sig.
Vertigo - - - Non-sig. - - -
Myelitis - - - - Non-sig. Non-sig. Non-sig.
Encephalomyelitis - - - - Non-sig. - Non-sig.
Encephalitis - - - - - Non-sig. -
Meningitis - - - - - Non-sig. -
Myasthenic disorder - - - - - Non-sig. -
Demyelinating events - - - - - Non-sig. -

Abbreviations/acronyms: EC: excess cases; RR: risk or relative ratio. Notes: (i) non-sig. means not statistically significant; (ii) if EC is not provided, it is not available; (iii) hyphen (-) denotes not available, that is, unexamined.